Literature DB >> 7687762

KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells.

R Zakut1, R Perlis, S Eliyahu, Y Yarden, D Givol, S D Lyman, R Halaban.   

Abstract

Previous studies in vivo and in vitro show that KIT kinase promotes normal melanocyte development and growth. However, the role of the KIT proto-oncogene in neoplastic melanocytes is not certain. We therefore examined KIT expression and function in human melanomas. Our results show that KIT mRNA was expressed in 12 of 28 melanoma cell lines (approximately 40%), mainly in those originating from pigmented tumors. Surprisingly, activation of KIT with mast cell growth factor (MGF) in melanoma cells produced biological responses opposite to those elicited in normal melanocytes. MGF inhibited rather than stimulated the growth of metastatic melanoma cell lines. The opposite effects may be due to aberrant signal transduction by KIT in melanoma cells in response to MGF. The in vitro inhibition of melanoma cells by MGF suggests that growth in vivo of this tumor is not promoted by KIT kinase activation, but rather that transformed melanocytes might regress when MGF is expressed in their immediate environment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687762

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.

Authors:  M Wu; T J Hemesath; C M Takemoto; M A Horstmann; A G Wells; E R Price; D Z Fisher; D E Fisher
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

2.  Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis.

Authors:  M Luca; S Huang; J E Gershenwald; R K Singh; R Reich; M Bar-Eli
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells.

Authors:  R Halaban; E Cheng; Y Zhang; G Moellmann; D Hanlon; M Michalak; V Setaluri; D N Hebert
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.

Authors:  James V Neiswender; Robert L Kortum; Caitlin Bourque; Melissa Kasheta; Leonard I Zon; Deborah K Morrison; Craig J Ceol
Journal:  Cancer Res       Date:  2017-09-25       Impact factor: 12.701

Review 5.  Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.

Authors:  Yunyi Kong; Suresh M Kumar; Xiaowei Xu
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

6.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.

Authors:  Carlos A Torres-Cabala; Wei-Lien Wang; Jonathan Trent; Dan Yang; Su Chen; John Galbincea; Kevin B Kim; Scott Woodman; Michael Davies; Jose A Plaza; J W Nash; Victor G Prieto; Alexander J Lazar; Doina Ivan
Journal:  Mod Pathol       Date:  2009-08-28       Impact factor: 7.842

8.  Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.

Authors:  S Huang; D Jean; M Luca; M A Tainsky; M Bar-Eli
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

9.  KIT is a frequent target for epigenetic silencing in cutaneous melanoma.

Authors:  Christina Dahl; Cecilie Abildgaard; Rikke Riber-Hansen; Torben Steiniche; Johanne Lade-Keller; Per Guldberg
Journal:  J Invest Dermatol       Date:  2014-09-01       Impact factor: 8.551

10.  Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.

Authors:  Astrid Rohrbeck; Jürgen Borlak
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.